Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal Kinase (JNK)

Journal of Biological Chemistry

Volumn 287, Issue 21, 2012, Pages 17682-17692

  Shajahan, Ayesha N ^a   Dobbin, Zachary C ^a   Hickman, F Edward ^a   Dakshanamurthy, Sivanesan ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CANCER CELLS; C-JUN N-TERMINAL KINASE; CAVEOLIN-1; CELL SURVIVAL; CELLULAR FUNCTION; CHEMOTHERAPEUTIC DRUGS; ESTROGEN RECEPTOR; LOW DOSE; MCF-7 CELLS; MITOCHONDRIAL APOPTOSIS; PACLITAXEL; SMALL MOLECULE INHIBITOR; STRUCTURAL HOMOLOGY; TUMOR RESPONSE; WILD TYPES;

AMINO ACIDS; CELL DEATH; ELECTRIC RESISTANCE;

PHOSPHORYLATION;

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CAVEOLIN 1; CAVEOLIN 1ALPHA; CAVEOLIN 1BETA; ESTROGEN RECEPTOR ALPHA; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; STRESS ACTIVATED PROTEIN KINASE; TYROSINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CAVEOLIN 1; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAP KINASE KINASE 4; MITOCHONDRIA; MUTATION, MISSENSE; PACLITAXEL; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84861205463     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.304022     Document Type: Article

References (48)

1. Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., Fleming, G., Holland, J. F., Duggan, D. B., Carpenter, J. T., Frei, E., 3rd, Schilsky, R. L., Wood, W. C., Muss, H. B., and Norton, L. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976-983 (Pubitemid 46594124)
2. Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., and Wolmark, N. (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. 23, 3686-3696
3. Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Van Vreckem, A., Sylvester, R., Awada, A., Wildiers, J., and Piccart, M. (2000) Paclitaxel versus doxorubicin as firstline single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J. Clin. Oncol. 18, 724-733 (Pubitemid 30106602)
4. McGrogan, B. T., Gilmartin, B., Carney, D. N., and McCann, A. (2008) Taxanes, microtubules, and chemoresistant breast cancer. Biochim. Biophys. Acta 1785, 96-132
5. Danial, N. N., and Korsmeyer, S. J. (2004) Cell death: critical control points. Cell 116, 205-219 (Pubitemid 38167313)
6. Burgermeister, E., Liscovitch, M., Röcken, C., Schmid, R. M., and Ebert, M. P. (2008) Caveats of caveolin-1 in cancer progression. Cancer Lett. 268, 187-201
7. Goetz, J. G., Lajoie, P., Wiseman, S. M., and Nabi, I. R. (2008) Caveolin-1 in tumor progression: the good, the bad, and the ugly. Cancer Metastasis Rev. 27, 715-735
8. Scherer, P. E., Tang, Z., Chun, M., Sargiacomo, M., Lodish, H. F., and Lisanti, M. P. (1995) Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution: identification and epitope mapping of an isoform-specific monoclonal antibody probe. J. Biol. Chem. 270, 16395-16401
9. Li, S., Couet, J., and Lisanti, M. P. (1996) Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin: caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 271, 29182-29190 (Pubitemid 26382628)
10. Li, S., Seitz, R., and Lisanti, M. P. (1996) Phosphorylation of caveolin by Src tyrosine kinases: the α-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J. Biol. Chem. 271, 3863-3868
11. Liu, P., Li, W. P., Machleidt, T., and Anderson, R. G. (1999) Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat. Cell Biol. 1, 369-375 (Pubitemid 129493580)
12. Machleidt, T., Li, W. P., Liu, P., and Anderson, R. G. (2000) Multiple domains in caveolin-1 control its intracellular traffic. J. Cell Biol. 148, 17-28 (Pubitemid 30046779)
13. Quest, A. F., Gutierrez-Pajares, J. L., and Torres, V. A. (2008) Caveolin-1: an ambiguous partner in cell signaling and cancer. J. Cell Mol. Med. 12, 1130-1150
14. Patani, N., Martin, L. A., Reis-Filho, J. S., and Dowsett, M. (2012) The role of caveolin-1 in human breast cancer. Breast Cancer Res. Treat. 131, 1-15
15. Hurlstone, A. F., Reid, G., Reeves, J. R., Fraser, J., Strathdee, G., Rahilly, M., Parkinson, E. K., and Black, D. M. (1999) Analysis of the caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene 18, 1881-1890 (Pubitemid 29145855)
16. Savage, K., Lambros, M. B., Robertson, D., Jones, R. L., Jones, C., Mackay, A., James, M., Hornick, J. L., Pereira, E. M., Milanezi, F., Fletcher, C. D., Schmitt, F. C., Ashworth, A., and Reis-Filho, J. S. (2007) Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13, 90-101 (Pubitemid 46121857)
17. Fang, P. K., Solomon, K. R., Zhuang, L., Qi, M., McKee, M., Freeman, M. R., and Yelick, P. C. (2006) Caveolin-1α and -1β perform nonredundant roles in early vertebrate development. Am. J. Pathol. 169, 2209-2222 (Pubitemid 351181979)
18. Shajahan, A. N., Wang, A., Decker, M., Minshall, R. D., Liu, M. C., and Clarke, R. (2007) Caveolin-1 tyrosine phosphorylation enhances paclitaxel- mediated cytotoxicity. J. Biol. Chem. 282, 5934-5943 (Pubitemid 47093784)
19. Fang, Y., Yan, J., Ding, L., Liu, Y., Zhu, J., Huang, C., Zhao, H., Lu, Q., Zhang, X., Yang, X., and Ye, Q. (2004) XBP-1 increases ERα transcriptional activity through regulation of large-scale chromatin unfolding. Biochem. Biophys. Res. Commun. 323, 269-274 (Pubitemid 39200679)
20. Kutuk, O., and Letai, A. (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 68, 7985-7994
21. Bouker, K. B., Skaar, T. C., Fernandez, D. R., O'Brien, K. A., Riggins, R. B., Cao, D., and Clarke, R. (2004) Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal anti-estrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Res. 64, 4030-4039 (Pubitemid 38701758)
22. Shajahan, A. N., Timblin, B. K., Sandoval, R., Tiruppathi, C., Malik, A. B., and Minshall, R. D. (2004) Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J. Biol. Chem. 279, 20392-20400 (Pubitemid 38623486)
23. Case, D. A., Darden, T. A., Cheatham, T. E., Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Pearlman, D. A., Crowley, M., Walker, R. C., Zhang, W., Wang, B., Hayik, S., Roitberg, A., Seabra, G., Wong, K. F., Paesani, F., Wu, X., Brozell, S., Tsui, V., Gohlke, H., Yang, L., Tan, C., Mongan, J., Hornak, V., Cui, G., Beroza, P., Mathews, D. H., Schafmeister, C., Ross, W. S., Kollman, P. A., and (2006) AMBER 9, University of California, San Francisco, CA
24. Hanson, R. N., Lee, C. Y., Friel, C. J., Dilis, R., Hughes, A., and DeSombre, E. R. (2003) Synthesis and evaluation of 17α-20E-21-(4- substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as probes for the estrogen receptor α hormone binding domain. J. Med. Chem. 46, 2865-2876 (Pubitemid 36775913)
25. Berendsen, H. J. C., Postma, J. P. M., Vangunsteren, W. F., Dinola, A., and Haak, J. R. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684-3690
26. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: an N.Log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089-10092
27. Romanelli, S., Perego, P., Pratesi, G., Carenini, N., Tortoreto, M., and Zunino, F. (1998) In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. 41, 385-390 (Pubitemid 28095754)
28. Basu, A., You, S. A., and Haldar, S. (2000) Regulation of Bcl2 phosphorylation by stress response kinase pathway. Int. J. Oncol. 16, 497-500
29. Basu, A., and Haldar, S. (2003) Identification of a novel Bcl-xL phospho-rylation site regulating the sensitivity of taxol- or 2-methoxyestradiolinduced apoptosis. FEBS Lett. 538, 41-47 (Pubitemid 36287422)
30. Basu, A., DuBois, G., and Haldar, S. (2006) Posttranslational modifications of Bcl2 family members: a potential therapeutic target for human malignancy. Front Biosci. 11, 1508-1521
31. Yamamoto, K., Ichijo, H., and Korsmeyer, S. J. (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell Biol. 19, 8469-8478 (Pubitemid 30414041)
32. Davis, R. J. (2000) Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252
33. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S., Nimmer, P. M., O'Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M. D., Zhang, H., Fesik, S. W., and Rosenberg, S. H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 435, 677-681 (Pubitemid 40825512)
34. Couet, J., Li, S., Okamoto, T., Ikezu, T., and Lisanti, M. P. (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain: implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272, 6525-6533 (Pubitemid 27118133)
35. Ahmed, N., Dasari, S., Srivastava, S. S., Sneh, A., Ahmad, A., Islam Khan, M., and Krishnasastry, M. V. (2008) Taxol and 10-deacetylbaccatin III induce distinct changes in the dynamics of caveolae. FEBS Lett. 582, 3595-3600
36. MacKeigan, J. P., Collins, T. S., and Ting, J. P. (2000) MEK inhibition enhances paclitaxel-induced tumor apoptosis. J. Biol. Chem. 275, 38953-38956 (Pubitemid 32058904)
37. Seidman, R., Gitelman, I., Sagi, O., Horwitz, S. B., and Wolfson, M. (2001) The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp. Cell Res. 268, 84-92 (Pubitemid 32678863)
38. Lee, L. F., Li, G., Templeton, D. J., and Ting, J. P. (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J. Biol. Chem. 273, 28253-28260 (Pubitemid 28496124)
39. Sunters, A., Madureira, P. A., Pomeranz, K. M., Aubert, M., Brosens, J. J., Cook, S. J., Burgering, B. M., Coombes, R. C., and Lam, E. W. (2006) Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 66, 212-220 (Pubitemid 43166027)
40. 2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 58, 241-247
41. Boldt, S., Weidle, U. H., and Kolch, W. (2002) The role ofMAPKpathways in the action of chemotherapeutic drugs. Carcinogenesis 23, 1831-1838 (Pubitemid 35355933)
42. Selimovic, D., Hassan, M., Haikel, Y., and Hengge, U. R. (2008) Taxolinduced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal. 20, 311-322
43. Blagosklonny, M. V. (2001) Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays 23, 947-953
44. Ferlini, C., Raspaglio, G., Mozzetti, S., Distefano, M., Filippetti, F., Martinelli, E., Ferrandina, G., Gallo, D., Ranelletti, F. O., and Scambia, G. (2003) Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 64, 51-58 (Pubitemid 36759817)
45. Luo, D., Cheng, S. C., Xie, H., and Xie, Y. (2000) Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem. Cell Biol. 78, 119-126 (Pubitemid 30353769)
46. Pawson, T., and Scott, J. D. (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278, 2075-2080 (Pubitemid 28028310)
47. Sverdlov, M., Shajahan, A. N., and Minshall, R. D. (2007) Tyrosine phosphorylation dependence of caveolae-mediated endocytosis. J. Cell Mol. Med. 11, 1239-1250
48. Tabuchi, Y., Matsuoka, J., Gunduz, M., Imada, T., Ono, R., Ito, M., Motoki, T., Yamatsuji, T., Shirakawa, Y., Takaoka, M., Haisa, M., Tanaka, N., Kurebayashi, J., Jordan, V. C., and Naomoto, Y. (2009) Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptormediated pathway in breast cancer. Int. J. Oncol. 34, 313-319